高力価医薬品有効成分（API）の世界市場（～2026年）

• 英文タイトル：Global High Potency Active Pharmaceutical Ingredients (APIs) Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY01212
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、154ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は高力価医薬品有効成分（API）のグローバル市場について調査・分析したレポートです。種類別（合成、バイオテクノロジー）市場規模、用途別（腫瘍学、ホルモン、緑内障、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別高力価医薬品有効成分（API）の競争状況、市場シェア
・世界の高力価医薬品有効成分（API）市場：種類別市場規模 2015年-2020年（合成、バイオテクノロジー）
・世界の高力価医薬品有効成分（API）市場：種類別市場規模予測 2021年-2026年（合成、バイオテクノロジー）
・世界の高力価医薬品有効成分（API）市場：用途別市場規模 2015年-2020年（腫瘍学、ホルモン、緑内障、その他）
・世界の高力価医薬品有効成分（API）市場：用途別市場規模予測 2021年-2026年（腫瘍学、ホルモン、緑内障、その他）
・北米の高力価医薬品有効成分（API）市場分析：米国、カナダ
・ヨーロッパの高力価医薬品有効成分（API）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの高力価医薬品有効成分（API）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の高力価医薬品有効成分（API）市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの高力価医薬品有効成分（API）市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Lonza、Novartis International AG、BASF AG、Carbogen Amcis AG、Eli Lilly and Company、Teva Pharmaceutical Industries Ltd、Bristol-Myers Squibb、Pfizer Inc.、Roche Diagnostics.、Hospira Inc、Boehringer Ingelheim、Medtronic、Merck & Co、Bayer AG、Sigma-Aldrich Corporation、Sanofi Aventis.
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

High Potency Active Pharmaceutical Ingredients (APIs) have higher active level targeting sever diseases such as tumour cells, infected cells, damaged organs than regular medicine elements.
Highly potent APIs are capable of targeting diseased cell selectively and more precisely than other compounds. Increasing incidence of cancer resulted in increasing R&D pertaining to anticancer drugs which thereby propelling the demand for HPAPIs over the forecast period. In addition, rising usage of HPAPI in gynecology & cosmetics are accounted for the further growth.

Market Analysis and Insights: Global High Potency Active Pharmaceutical Ingredients (APIs) Market
The global High Potency Active Pharmaceutical Ingredients (APIs) market size is projected to reach US$ 15650 million by 2026, from US$ 14890 million in 2020, at a CAGR of 4.7%% during 2021-2026.

Global High Potency Active Pharmaceutical Ingredients (APIs) Scope and Market Size
High Potency Active Pharmaceutical Ingredients (APIs) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global High Potency Active Pharmaceutical Ingredients (APIs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the High Potency Active Pharmaceutical Ingredients (APIs) market is segmented into
Synthetic
Biotech

Segment by Application, the High Potency Active Pharmaceutical Ingredients (APIs) market is segmented into
Oncology
Hormonal
Glaucoma
Others

Regional and Country-level Analysis
The High Potency Active Pharmaceutical Ingredients (APIs) market is analysed and market size information is provided by regions (countries).
The key regions covered in the High Potency Active Pharmaceutical Ingredients (APIs) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and High Potency Active Pharmaceutical Ingredients (APIs) Market Share Analysis
High Potency Active Pharmaceutical Ingredients (APIs) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in High Potency Active Pharmaceutical Ingredients (APIs) business, the date to enter into the High Potency Active Pharmaceutical Ingredients (APIs) market, High Potency Active Pharmaceutical Ingredients (APIs) product introduction, recent developments, etc.

The major vendors covered:
Lonza
Novartis International AG
BASF AG
Carbogen Amcis AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb
Pfizer Inc.
Roche Diagnostics.
Hospira Inc
Boehringer Ingelheim
Medtronic
Merck & Co
Bayer AG
Sigma-Aldrich Corporation
Sanofi Aventis.

レポート目次

1 Study Coverage
1.1 High Potency Active Pharmaceutical Ingredients (APIs) Product Introduction
1.2 Market Segments
1.3 Key High Potency Active Pharmaceutical Ingredients (APIs) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Type
1.4.2 Synthetic
1.4.3 Biotech
1.5 Market by Application
1.5.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Application
1.5.2 Oncology
1.5.3 Hormonal
1.5.4 Glaucoma
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size, Estimates and Forecasts
2.1.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue 2015-2026
2.1.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales 2015-2026
2.2 Global High Potency Active Pharmaceutical Ingredients (APIs), Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global High Potency Active Pharmaceutical Ingredients (APIs) Competitor Landscape by Players
3.1 High Potency Active Pharmaceutical Ingredients (APIs) Sales by Manufacturers
3.1.1 High Potency Active Pharmaceutical Ingredients (APIs) Sales by Manufacturers (2015-2020)
3.1.2 High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Manufacturers (2015-2020)
3.2 High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Manufacturers
3.2.1 High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Manufacturers (2015-2020)
3.2.2 High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by High Potency Active Pharmaceutical Ingredients (APIs) Revenue in 2019
3.2.5 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 High Potency Active Pharmaceutical Ingredients (APIs) Price by Manufacturers
3.4 High Potency Active Pharmaceutical Ingredients (APIs) Manufacturing Base Distribution, Product Types
3.4.1 High Potency Active Pharmaceutical Ingredients (APIs) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Product Type
3.4.3 Date of International Manufacturers Enter into High Potency Active Pharmaceutical Ingredients (APIs) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size by Type (2015-2020)
4.1.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020)
4.1.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Type (2015-2020)
4.1.3 High Potency Active Pharmaceutical Ingredients (APIs) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Type (2021-2026)
4.2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Type (2021-2026)
4.2.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Type (2021-2026)
4.2.3 High Potency Active Pharmaceutical Ingredients (APIs) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size by Application (2015-2020)
5.1.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020)
5.1.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Application (2015-2020)
5.1.3 High Potency Active Pharmaceutical Ingredients (APIs) Price by Application (2015-2020)
5.2 High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Application (2021-2026)
5.2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Application (2021-2026)
5.2.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Application (2021-2026)
5.2.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Price Forecast by Application (2021-2026)

6 North America
6.1 North America High Potency Active Pharmaceutical Ingredients (APIs) by Country
6.1.1 North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
6.1.2 North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Type
6.3 North America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Application

7 Europe
7.1 Europe High Potency Active Pharmaceutical Ingredients (APIs) by Country
7.1.1 Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
7.1.2 Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Type
7.3 Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) by Region
8.1.1 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Region
8.1.2 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Type
8.3 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Application

9 Latin America
9.1 Latin America High Potency Active Pharmaceutical Ingredients (APIs) by Country
9.1.1 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
9.1.2 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Type
9.3 Central & South America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) by Country
10.1.1 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
10.1.2 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Type
10.3 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Application

11 Company Profiles
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Description and Business Overview
11.1.3 Lonza Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Lonza High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.1.5 Lonza Related Developments
11.2 Novartis International AG
11.2.1 Novartis International AG Corporation Information
11.2.2 Novartis International AG Description and Business Overview
11.2.3 Novartis International AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.2.5 Novartis International AG Related Developments
11.3 BASF AG
11.3.1 BASF AG Corporation Information
11.3.2 BASF AG Description and Business Overview
11.3.3 BASF AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.3.5 BASF AG Related Developments
11.4 Carbogen Amcis AG
11.4.1 Carbogen Amcis AG Corporation Information
11.4.2 Carbogen Amcis AG Description and Business Overview
11.4.3 Carbogen Amcis AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.4.5 Carbogen Amcis AG Related Developments
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Corporation Information
11.5.2 Eli Lilly and Company Description and Business Overview
11.5.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.5.5 Eli Lilly and Company Related Developments
11.6 Teva Pharmaceutical Industries Ltd
11.6.1 Teva Pharmaceutical Industries Ltd Corporation Information
11.6.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
11.6.3 Teva Pharmaceutical Industries Ltd Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.6.5 Teva Pharmaceutical Industries Ltd Related Developments
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Description and Business Overview
11.7.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.7.5 Bristol-Myers Squibb Related Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Corporation Information
11.8.2 Pfizer Inc. Description and Business Overview
11.8.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.8.5 Pfizer Inc. Related Developments
11.9 Roche Diagnostics.
11.9.1 Roche Diagnostics. Corporation Information
11.9.2 Roche Diagnostics. Description and Business Overview
11.9.3 Roche Diagnostics. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.9.5 Roche Diagnostics. Related Developments
11.10 Hospira Inc
11.10.1 Hospira Inc Corporation Information
11.10.2 Hospira Inc Description and Business Overview
11.10.3 Hospira Inc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.10.5 Hospira Inc Related Developments
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Description and Business Overview
11.1.3 Lonza Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Lonza High Potency Active Pharmaceutical Ingredients (APIs) Products Offered
11.1.5 Lonza Related Developments
11.12 Medtronic
11.12.1 Medtronic Corporation Information
11.12.2 Medtronic Description and Business Overview
11.12.3 Medtronic Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Medtronic Products Offered
11.12.5 Medtronic Related Developments
11.13 Merck & Co
11.13.1 Merck & Co Corporation Information
11.13.2 Merck & Co Description and Business Overview
11.13.3 Merck & Co Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Merck & Co Products Offered
11.13.5 Merck & Co Related Developments
11.14 Bayer AG
11.14.1 Bayer AG Corporation Information
11.14.2 Bayer AG Description and Business Overview
11.14.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Bayer AG Products Offered
11.14.5 Bayer AG Related Developments
11.15 Sigma-Aldrich Corporation
11.15.1 Sigma-Aldrich Corporation Corporation Information
11.15.2 Sigma-Aldrich Corporation Description and Business Overview
11.15.3 Sigma-Aldrich Corporation Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Sigma-Aldrich Corporation Products Offered
11.15.5 Sigma-Aldrich Corporation Related Developments
11.16 Sanofi Aventis.
11.16.1 Sanofi Aventis. Corporation Information
11.16.2 Sanofi Aventis. Description and Business Overview
11.16.3 Sanofi Aventis. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Sanofi Aventis. Products Offered
11.16.5 Sanofi Aventis. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 High Potency Active Pharmaceutical Ingredients (APIs) Market Estimates and Projections by Region
12.1.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Regions 2021-2026
12.1.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Regions 2021-2026
12.2 North America High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast (2021-2026)
12.2.1 North America: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast (2021-2026)
12.2.2 North America: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast (2021-2026)
12.2.3 North America: High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Country (2021-2026)
12.3 Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast (2021-2026)
12.3.1 Europe: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast (2021-2026)
12.3.2 Europe: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast (2021-2026)
12.3.3 Europe: High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Region (2021-2026)
12.5 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast (2021-2026)
12.5.1 Latin America: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast (2021-2026)
12.5.2 Latin America: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast (2021-2026)
12.5.3 Latin America: High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: High Potency Active Pharmaceutical Ingredients (APIs) Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key High Potency Active Pharmaceutical Ingredients (APIs) Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 High Potency Active Pharmaceutical Ingredients (APIs) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. High Potency Active Pharmaceutical Ingredients (APIs) Market Segments
Table 2. Ranking of Global Top High Potency Active Pharmaceutical Ingredients (APIs) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Synthetic
Table 5. Major Manufacturers of Biotech
Table 6. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Application 2020-2026 (K Units)
Table 7. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 8. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Regions 2015-2020 (K Units)
Table 9. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Regions (2015-2020)
Table 10. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Manufacturers (2015-2020) (K Units)
Table 12. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Share by Manufacturers (2015-2020)
Table 13. Global High Potency Active Pharmaceutical Ingredients (APIs) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global High Potency Active Pharmaceutical Ingredients (APIs) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency Active Pharmaceutical Ingredients (APIs) as of 2019)
Table 15. High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Price (2015-2020) (USD/Unit)
Table 18. High Potency Active Pharmaceutical Ingredients (APIs) Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Product Type
Table 20. Date of International Manufacturers Enter into High Potency Active Pharmaceutical Ingredients (APIs) Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 23. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Share by Type (2015-2020)
Table 24. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Type (2015-2020) (US$ Million)
Table 25. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Type (2015-2020)
Table 26. High Potency Active Pharmaceutical Ingredients (APIs) Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 27. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 28. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Share by Application (2015-2020)
Table 29. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2015-2020) (K Units)
Table 30. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2015-2020)
Table 31. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2015-2020) (US$ Million)
Table 32. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2015-2020)
Table 33. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 34. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Table 35. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 36. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Table 37. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2015-2020) (K Units)
Table 38. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2015-2020)
Table 39. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2015-2020)
Table 41. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 42. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Table 43. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 44. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Region (2015-2020) (K Units)
Table 46. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 50. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 52. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Table 53. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2015-2020) (K Units)
Table 54. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2015-2020)
Table 57. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 58. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Table 59. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 60. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2015-2020) (K Units)
Table 62. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Type (2015-2020) (K Units)
Table 66. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Application (2015-2020) (K Units)
Table 68. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Table 69. Lonza Corporation Information
Table 70. Lonza Description and Major Businesses
Table 71. Lonza High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 72. Lonza Product
Table 73. Lonza Recent Development
Table 74. Novartis International AG Corporation Information
Table 75. Novartis International AG Description and Major Businesses
Table 76. Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 77. Novartis International AG Product
Table 78. Novartis International AG Recent Development
Table 79. BASF AG Corporation Information
Table 80. BASF AG Description and Major Businesses
Table 81. BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 82. BASF AG Product
Table 83. BASF AG Recent Development
Table 84. Carbogen Amcis AG Corporation Information
Table 85. Carbogen Amcis AG Description and Major Businesses
Table 86. Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 87. Carbogen Amcis AG Product
Table 88. Carbogen Amcis AG Recent Development
Table 89. Eli Lilly and Company Corporation Information
Table 90. Eli Lilly and Company Description and Major Businesses
Table 91. Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 92. Eli Lilly and Company Product
Table 93. Eli Lilly and Company Recent Development
Table 94. Teva Pharmaceutical Industries Ltd Corporation Information
Table 95. Teva Pharmaceutical Industries Ltd Description and Major Businesses
Table 96. Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 97. Teva Pharmaceutical Industries Ltd Product
Table 98. Teva Pharmaceutical Industries Ltd Recent Development
Table 99. Bristol-Myers Squibb Corporation Information
Table 100. Bristol-Myers Squibb Description and Major Businesses
Table 101. Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 102. Bristol-Myers Squibb Product
Table 103. Bristol-Myers Squibb Recent Development
Table 104. Pfizer Inc. Corporation Information
Table 105. Pfizer Inc. Description and Major Businesses
Table 106. Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 107. Pfizer Inc. Product
Table 108. Pfizer Inc. Recent Development
Table 109. Roche Diagnostics. Corporation Information
Table 110. Roche Diagnostics. Description and Major Businesses
Table 111. Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 112. Roche Diagnostics. Product
Table 113. Roche Diagnostics. Recent Development
Table 114. Hospira Inc Corporation Information
Table 115. Hospira Inc Description and Major Businesses
Table 116. Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Hospira Inc Product
Table 118. Hospira Inc Recent Development
Table 119. Boehringer Ingelheim Corporation Information
Table 120. Boehringer Ingelheim Description and Major Businesses
Table 121. Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Boehringer Ingelheim Product
Table 123. Boehringer Ingelheim Recent Development
Table 124. Medtronic Corporation Information
Table 125. Medtronic Description and Major Businesses
Table 126. Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 127. Medtronic Product
Table 128. Medtronic Recent Development
Table 129. Merck & Co Corporation Information
Table 130. Merck & Co Description and Major Businesses
Table 131. Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 132. Merck & Co Product
Table 133. Merck & Co Recent Development
Table 134. Bayer AG Corporation Information
Table 135. Bayer AG Description and Major Businesses
Table 136. Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 137. Bayer AG Product
Table 138. Bayer AG Recent Development
Table 139. Sigma-Aldrich Corporation Corporation Information
Table 140. Sigma-Aldrich Corporation Description and Major Businesses
Table 141. Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 142. Sigma-Aldrich Corporation Product
Table 143. Sigma-Aldrich Corporation Recent Development
Table 144. Sanofi Aventis. Corporation Information
Table 145. Sanofi Aventis. Description and Major Businesses
Table 146. Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 147. Sanofi Aventis. Product
Table 148. Sanofi Aventis. Recent Development
Table 149. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Regions (2021-2026) (K Units)
Table 150. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share Forecast by Regions (2021-2026)
Table 151. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 152. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share Forecast by Regions (2021-2026)
Table 153. North America: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Country (2021-2026) (K Units)
Table 154. North America: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Europe: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Country (2021-2026) (K Units)
Table 156. Europe: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 157. Asia Pacific: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Region (2021-2026) (K Units)
Table 158. Asia Pacific: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 159. Latin America: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Country (2021-2026) (K Units)
Table 160. Latin America: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 161. Middle East and Africa: High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Country (2021-2026) (K Units)
Table 162. Middle East and Africa: High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 164. Key Challenges
Table 165. Market Risks
Table 166. Main Points Interviewed from Key High Potency Active Pharmaceutical Ingredients (APIs) Players
Table 167. High Potency Active Pharmaceutical Ingredients (APIs) Customers List
Table 168. High Potency Active Pharmaceutical Ingredients (APIs) Distributors List
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. High Potency Active Pharmaceutical Ingredients (APIs) Product Picture
Figure 2. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type in 2020 & 2026
Figure 3. Synthetic Product Picture
Figure 4. Biotech Product Picture
Figure 5. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application in 2020 & 2026
Figure 6. Oncology
Figure 7. Hormonal
Figure 8. Glaucoma
Figure 9. Others
Figure 10. High Potency Active Pharmaceutical Ingredients (APIs) Report Years Considered
Figure 11. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size 2015-2026 (US$ Million)
Figure 12. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales 2015-2026 (K Units)
Figure 13. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region (2015-2020)
Figure 15. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region in 2019
Figure 16. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region (2015-2020)
Figure 17. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region in 2019
Figure 18. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by High Potency Active Pharmaceutical Ingredients (APIs) Revenue in 2019
Figure 20. High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2015-2020)
Figure 22. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type in 2019
Figure 23. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Type (2015-2020)
Figure 24. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Type in 2019
Figure 25. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Price Range (2015-2020)
Figure 26. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2015-2020)
Figure 27. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application in 2019
Figure 28. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Application (2015-2020)
Figure 29. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Application in 2019
Figure 30. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country in 2019
Figure 33. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country in 2019
Figure 34. U.S. High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2019
Figure 39. North America High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2019
Figure 40. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country in 2019
Figure 43. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country in 2019
Figure 44. Germany High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 47. France High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2019
Figure 55. Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2019
Figure 56. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region in 2019
Figure 59. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region in 2019
Figure 60. China High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 61. China High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 67. India High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2019
Figure 83. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2019
Figure 84. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country in 2019
Figure 87. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country in 2019
Figure 88. Mexico High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2019
Figure 95. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2019
Figure 96. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country in 2019
Figure 99. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country in 2019
Figure 100. Turkey High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2019
Figure 107. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2019
Figure 108. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed

以下、関連資料のご紹介

高薬理活性原薬 (HPAPI)の世界市場（～2026年）

Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Size, Status and Forecast 2020-2026
MRC2-11QY12187 2020年11月25日 98Pages
当調査資料は高薬理活性原薬 (HPAPI)のグローバル市場について調査・分析したレポートです。種類別（合成HPAPI、バイオテクノロジーHPAPI）市場規模、用途別（中枢神経系障害、腫瘍学、ホルモン障害、緑内障、感染症、代謝障害、心血管、炎症）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ...

HPAPI（高力価有効成分）の世界市場（～2026年）

Global HPAPI (High Potency Active Pharmaceutical Ingredients) Market Insights and Forecast to 2026
MRC2-11QY01411 2020年11月20日 111Pages
当調査資料はHPAPI（高力価有効成分）のグローバル市場について調査・分析したレポートです。種類別（革新的HPAPI、汎用HPAPI）市場規模、用途別（キャプティブHPAPI、マーチャントHPAPI）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...

高性能医薬品有効成分（HPAPI）の世界市場（～2026年）

Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Insights and Forecast to 2026
MRC2-11QY01193 2020年11月20日 112Pages
当調査資料は高性能医薬品有効成分（HPAPI）のグローバル市場について調査・分析したレポートです。種類別（合成成分、生物成分、その他）市場規模、用途別（腫瘍学、緑内障、抗糖尿病、心臓血管、筋骨格、ホルモン、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア...

ジェネリック医薬品有効成分の世界市場（～2026年）

Global Generic Active Pharmaceutical Ingredients Market Insights and Forecast to 2026
MRC2-11QY06747 2020年11月20日 118Pages
当調査資料はジェネリック医薬品有効成分のグローバル市場について調査・分析したレポートです。種類別（モノクローナル抗体、ホルモン、サイトカイン、融合タンパク質、治療用酵素、ワクチン、血液因子）市場規模、用途別（腫瘍学、糖尿病、心血管疾患、CNS・神経障害、内分泌学、その他）市場規模、地域別（北米、米国...

インスリン有効成分の世界市場（～2026年）

Global Insulin Active Pharmaceutical Ingredient Market Insights and Forecast to 2026
MRC2-11QY01752 2020年11月20日 110Pages
当調査資料はインスリン有効成分のグローバル市場について調査・分析したレポートです。種類別（化学合成、動物抽出物）市場規模、用途別（動物インスリン、通常ヒトインスリン、インスリンアナログ）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

パーソナルケア用有効成分の世界市場（～2026年）

Global Active Ingredients in Personal Care Market Insights and Forecast to 2026
MRC2-11QY02078 2020年11月20日 149Pages
当調査資料はパーソナルケア用有効成分のグローバル市場について調査・分析したレポートです。種類別（天然、合成）市場規模、用途別（スキンケア、ヘアケア、オーラルケア、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

医薬品有効成分の世界市場（～2026年）

Global Active Pharma Ingredient Market Insights and Forecast to 2026
MRC2-11QY02082 2020年11月20日 183Pages
当調査資料は医薬品有効成分のグローバル市場について調査・分析したレポートです。種類別（革新的医薬品有効成分、ジェネリック医薬品有効成分）市場規模、用途別（腫瘍学、心血管疾患、糖尿病、中枢神経系・神経障害、内分泌学、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

製薬植物抽出物の世界市場（～2026年）

Global Pharmaceutical Plant Extracts Market Insights and Forecast to 2026
MRC2-11QY13696 2020年11月30日 183Pages
当調査資料は製薬植物抽出物のグローバル市場について調査・分析したレポートです。種類別（非標準化抽出物、標準化抽出物）市場規模、用途別（医学、食品、化粧品、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

バイオアクティブプロテインの世界市場（～2026年）

Global Bio Active Protein Market Insights and Forecast to 2026
MRC2-11QY03141 2020年11月20日 118Pages
当調査資料はバイオアクティブプロテインのグローバル市場について調査・分析したレポートです。種類別（植物源、マメ科植物源、動物源、乳製品、その他）市場規模、用途別（がん、心臓病、化粧品、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

アクティブニュートリションの世界市場（～2026年）

Global Active Nutrition Market Insights and Forecast to 2026
MRC2-11QY02080 2020年11月20日 119Pages
当調査資料はアクティブニュートリションのグローバル市場について調査・分析したレポートです。種類別（消費者健康、清涼飲料、パッケージ食品）市場規模、用途別（スポーツ栄養、タンパク質サプリメント）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

高薬理活性原薬 (HPAPI)の世界市場（～2026年） The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) = 10µg/m3. Market Analysis and Insights: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market The global High Potency Active Pharmaceutical Ingredients (HPAPI) market size is projected to reach US$ XX m…
HPAPI（高力価有効成分）の世界市場（～2026年） Market Analysis and Insights: Global HPAPI (High Potency Active Pharmaceutical Ingredients) Market The global HPAPI (High Potency Active Pharmaceutical Ingredients) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global HPAPI…
高性能医薬品有効成分（HPAPI）の世界市場（～2026年） Market Analysis and Insights: Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market The global High Performance Active Pharmaceutical Ingredients (HPAPI) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Glob…
ジェネリック医薬品有効成分の世界市場（～2026年） Market Analysis and Insights: Global Generic Active Pharmaceutical Ingredients Market The global Generic Active Pharmaceutical Ingredients market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Generic Active Pharmaceutical I…
パーソナルケア用有効成分の世界市場（～2026年） The active ingredients in these products enter the wastewater collection system following hand-washing, bathing, and laundry-washing. North America was followed by Europe and Asia-Pacific as second and third largest market for the active ingredients in personal care market. Market Analysis and Insig…